نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013
Caitlin C Burke Valerie Martel-Laferriere Douglas T Dieterich

TO THE EDITOR—Telaprevir and bocepre-vir are protease inhibitors approved by the Food and Drug Administration for use in the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Common adverse events associated with boceprevir are anemia and dysgeusia, whereas rash and anemia are associated with telaprevir [1, 2]. We report 2 cases of infectious bursitis in patients undergoing the...

Journal: :Hepatology 2011
Jeremie Guedj Alan S Perelson

Hepatitis C virus (HCV) RNA decay during antiviral therapy is characterized by a rapid first phase, followed by a slower second phase. The current understanding of viral kinetics attributes the magnitude of the first phase of decay to treatment effectiveness, whereas the second phase of decay is attributed to the progressive loss of infected cells. Here, we analyzed data from 44 patients treate...

2014
Tatsuo Miyamura Tatsuo Kanda Shingo Nakamoto Makoto Arai Masato Nakamura Shuang Wu Xia Jiang Reina Sasaki Yuki Haga Shin Yasui Yoshihiko Ooka Tetsuhiro Chiba Fumio Imazeki Shigeru Mikami Osamu Yokosuka

Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein, associated with human antiviral defenses. We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response i...

Journal: :Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2011
Masahiro Takita Satoru Hagiwara Masatoshi Kudo Masashi Kouno Hirokazu Chishina Tadaaki Arizumi Satoshi Kitai Norihisa Yada Tatsuo Inoue Yasunori Minami Kazuomi Ueshima

BACKGROUND Telaprevir-based antiviral therapy has been the primary treatment for chronic hepatitis C genotype 1 at a high viral load since November 2011. On the other hand, a number of patients have been reported to require withdrawal from or reduced doses of drugs due to side effects, such as eruptions, anemia, and renal dysfunction. In addition, as hepatitis C patients are growing older, it i...

Journal: :Molecular pharmaceutics 2015
Laura I Mosquera-Giraldo Lynne S Taylor

Amorphous solid dispersions are of great current interest because they can improve the delivery of poorly water-soluble compounds. It has been recently noted that the highly supersaturated solutions generated by dissolution of some ASDs can undergo a phase transition to a colloidal, disordered, drug-rich phase when the concentration exceeds the "amorphous solubility" of the drug. The purpose of...

Journal: :Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2014
Koji Takayama Norihiro Furusyo Eiichi Ogawa Motohiro Shimizu Satoshi Hiramine Fujiko Mitsumoto Kazuya Ura Kazuhiro Toyoda Masayuki Murata Jun Hayashi

Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients wit...

Journal: :International journal of molecular medicine 2014
Fugui Bai Yoshihiko Yano Soo-Ryang Kim Yasushi Seo Akira Miki Masaya Saito Hirotaka Hirano Kenji Momose Akihiro Minami Yuri Hatazawa Takanobu Hayakumo Dewiyani Indah Widasari Hanggoro Tri Rinonce Masahiko Sugano Satoshi Tani Seitetsu Yoon Susumu Imoto Takeshi Azuma Hak Hotta Yoshitake Hayashi

Telaprevir, a non-structural (NS)3/4A protease inhibitor, is a direct-acting antiviral drug that inhibits viral replication. Triple therapy with telaprevir, pegylated interferon, and ribavirin is a standard therapeutic regimen for patients with genotype 1b chronic hepatitis C virus (HCV) infection and a high viral load. Several factors, including mutations in the NS5A gene, are important predic...

Journal: :Clinics and research in hepatology and gastroenterology 2015
François Bailly Victor Virlogeux Cécilie Dufour Pierre Pradat Christophe Hézode Dominique Larrey Laurent Alric Didier Samuel Marc Bourlière Sophie Métivier Jean-Pierre Zarski Hélène Fontaine Véronique Loustaud-Ratti Lawrence Serfaty Jean-Pierre Bronowicki Fabrice Carrat Fabien Zoulim

BACKGROUND AND OBJECTIVE To assess within the ANRS CO20-CUPIC cohort whether the viral load (VL) at week 2/week 6 for telaprevir/boceprevir-based triple therapy, respectively, was predictive of sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and to study the relevance of this measurement to early diagnose drug resistance. METHODS Observational study of ...

2015
Jayne Dillon Khalid Mumtaz Eberhard L Renner

Drug induced pancreatitis (DIP) is a serious adverse effect of many commonly used drugs. Pegylated interferon (pegIFN) and ribavirin used for treatment of chronic hepatitis C (CHC) infection and various protease inhibitors (PIs) such as indinavir, nelfinavir, ritonavir and saquinavir used for HIV infection have been reported to cause DIP; although the mechanism of pancreatitis is not well known...

Journal: :Swiss medical weekly 2012

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virolog...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید